TRPX - Therapix Biosciences Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 52.46M
Enterprise Value 31.43M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)N/A
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-0.20

Trading Information

Stock Price History

Beta (5Y Monthly) 0.12
52-Week Change 3-84.07%
S&P500 52-Week Change 35.46%
52 Week High 34.6900
52 Week Low 30.2520
50-Day Moving Average 30.3609
200-Day Moving Average 30.7342

Share Statistics

Avg Vol (3 month) 31.79M
Avg Vol (10 day) 32.21M
Shares Outstanding 55.72M
Float 4.05M
% Held by Insiders 10.00%
% Held by Institutions 11.13%
Shares Short (Apr. 29, 2020) 4181.27k
Short Ratio (Apr. 29, 2020) 40.11
Short % of Float (Apr. 29, 2020) 4N/A
Short % of Shares Outstanding (Apr. 29, 2020) 43.17%
Shares Short (prior month Mar. 30, 2020) 455.78k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2018
Most Recent Quarter (mrq)Jun. 29, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-111.52%
Return on Equity (ttm)-362.77%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -7.27M
Net Income Avi to Common (ttm)-7.68M
Diluted EPS (ttm)-2.7980
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)1.59M
Total Cash Per Share (mrq)0.38
Total Debt (mrq)1.31M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)0.68
Book Value Per Share (mrq)-0.18

Cash Flow Statement

Operating Cash Flow (ttm)-6.56M
Levered Free Cash Flow (ttm)-3.01M